OmniAb Inc (OABI) Stock AnalysisOABIOmniAb Inc

OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

OmniAb Inc (OABI) is a good buy right now due to its significant revenue growth and positive analyst outlook. The company reported a 244% increase in revenue for Q2 2026, reaching $13.4 million, and has raised its 2026 revenue guidance to between $32 million and $36 million. Additionally, the stock is currently priced at $4.79, with an analyst price target of $6, indicating a potential upside of approximately 25%. The main risk is its negative net income, which was -5.9 million in Q2 2026, highlighting ongoing financial challenges.